|
|
||||||||
Department of Internal Medicine, Diabetes and Endocrinology Research Center, Veterans Administration Medical Center, The University of Iowa, Iowa City, Iowa 52246
Insulin-like growth
factor-binding protein-3 (IGFBP-3) was digested with plasmin, and the
proteolytic fragments were isolated by HPLC and tested for bioactivity
as measured by stimulation of glucose uptake in microvessel endothelial
cells. Two of the pooled fractions of the digest stimulated glucose
uptake. The major bioactive pool, at an estimated protein concentration
<50 ng/ml, stimulated glucose uptake to 150% of control with greater stimulation and 220% of control at ~250 ng/ml. Two fragments were present in the bioactive fraction, the dominant one migrating at
~20,000 and the other at ~8,000. Both fragments bound
125I-labeled insulin-like growth
factor and
[3H]heparin.
NH2-terminal amino acid analysis
of the bioactive peak yielded two sequences. One, representing the
majority of the material, had an
NH2-terminal sequence identical to
IGFBP-3; the second fragment began at amino acid 202 of IGFBP-3. In
contrast to the bioactive fragments, intact IGFBP-3, at concentrations
up to 130 µg/ml, had no bioactivity. These findings demonstrate that
IGFBP-3 can be degraded into fragments that have potent bioactivities that are not present in the intact IGFBP-3 molecule.
endothelium; insulin-like growth factor-binding protein-3; bioactivity
This article has been cited by other articles:
![]() |
B. A. Booth, M. Boes, B. L. Dake, K. L. Knudtson, and R. S. Bar IGFBP-3 binding to endothelial cells inhibits plasmin and thrombin proteolysis Am J Physiol Endocrinol Metab, January 1, 2002; 282(1): E52 - E58. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |